Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (331-340 of 386) with videos related to

Pageof 39
Sort By:
NPJ Breast Cancer|December 30, 2025
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancerMarie-France Jilderda, John M S Bartlett, Gerrit-Jan Liefers, et al.
Breast Cancer Research and Treatment|May 17, 2018
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerErik J Blok, Charla C Engels, Geeske Dekker-Ensink, et al.
Journal of the National Cancer Institute|June 20, 2018
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) TrialAntonia K Roseweir, Lindsay Bennett, Ashley Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trialJohn M S Bartlett, Cassandra L Brookes, Tammy Robson, et al.
Plos Computational Biology|January 11, 2019
Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancerDeena M A Gendoo, Robert E Denroche, Amy Zhang, et al.
Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to E.A. Rakha et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2012
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysisWillemien van de Water, Duveken B Y Fontein, Johanna G H van Nes, et al.
Journal of the National Cancer Institute|November 9, 2013
An international Ki67 reproducibility studyMei-Yin C Polley, Samuel C Y Leung, Lisa M McShane, et al.
Pageof 39

Showing results (331-340 of 386) with videos related to

Sort By:
Pageof 39
NPJ Breast Cancer|December 30, 2025
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancerMarie-France Jilderda, John M S Bartlett, Gerrit-Jan Liefers, et al.
Breast Cancer Research and Treatment|May 17, 2018
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerErik J Blok, Charla C Engels, Geeske Dekker-Ensink, et al.
Journal of the National Cancer Institute|June 20, 2018
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) TrialAntonia K Roseweir, Lindsay Bennett, Ashley Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trialJohn M S Bartlett, Cassandra L Brookes, Tammy Robson, et al.
Plos Computational Biology|January 11, 2019
Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancerDeena M A Gendoo, Robert E Denroche, Amy Zhang, et al.
Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to E.A. Rakha et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2012
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysisWillemien van de Water, Duveken B Y Fontein, Johanna G H van Nes, et al.
Journal of the National Cancer Institute|November 9, 2013
An international Ki67 reproducibility studyMei-Yin C Polley, Samuel C Y Leung, Lisa M McShane, et al.
Pageof 39